Tiffany Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tiffany Lin has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Eli Dabscheck
Allergy, Asthma and Clinical Immunology Service, Alfred Health, Melbourne, Australia
3 shared publications- Mark Hew
Alfred Hospital
3 shared publications Asger Sverrild
Department of Respiratory Medicine, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark
2 shared publicationsEve Denton
Allergy, Asthma and Clinical Immunology Service, Alfred Health, Melbourne, Australia
2 shared publications- Joy Lee
Austin Health, Melbourne, Victoria, Australia
2 shared publications - Julian J. Bosco
Asthma, Allergy and Clinical immunology, Alfred Hospital, VIC Australia
2 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 38, e16
Evaluating the efficacy of prednisolone for silicosis with progressive massive fibrosis in Australia: an observational pilot study
Background: There has been a resurgence of silicosis, particularly related to artificial stone. There are currently no treatments for silicosis beyond lung transplantation for end-stage disease. This study aimed to evaluate the efficacy of prednisolone in people with artificial stone-associated silicosis–progressive massive fibrosis (PMF).Methods: This was a pilot prospective observational clinical trial, assessing 3 months of prednisolone in adults with artificial stone–associated silicosis with PMF. Outcomes were assessed at 3 and 12 months.Results: Seven participants completed the study. Baseline positron emission tomography (PET) scans demonstrated increased fluorine-18 fluorodeoxyglucose (18F-FDG) uptake in areas of PMF in all participants. All participants had a significant reduction in maximum standardized uptake value (SUVmax) following prednisolone at 3 months (pre-treatment mean SUVmax 6.7 [standard deviation (SD): 2.6], post-treatment mean SUVmax 4.2 [SD: 1.0], p = 0.012). There was also a non-significant reduction in the % of total lung parenchyma with SUV >1 (49.7% [SD: 36.4] to 45.8% [SD: 28.4], p = 0.527) and a significant reduction in SUV >2.5 (7.0% [SD: 6.3] to 2.4% [SD: 2.2], p = 0.038). There was a non-significant reduction in computed tomography ICOERD well-defined opacity profusion scores and large opacities. There was no significant difference in lung function or St. George's Respiratory Questionnaire. There were no serious adverse events.Conclusions: There are high levels of inflammation in silicosis-PMF as evidenced by 18F-FDG PET. Short-term prednisolone reduced 18F-FDG PET activity. This suggests a possible therapeutic pathway for people with silicosis-associated PMF in a population with no current treatments. Further research is required to determine the most appropriate immunosuppressive strategy and further assess longer-term outcomes.
- 4 June 2026
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 38, e16
Open AccessEvaluating the efficacy of prednisolone for silicosis with progressive massive fibrosis in Australia: an observational pilot study
Background: There has been a resurgence of silicosis, particularly related to artificial stone. There are currently no treatments for silicosis beyond lung transplantation for end-stage disease. This study aimed to evaluate the efficacy of prednisolone in people with artificial stone-associated silicosis–progressive massive fibrosis (PMF).Methods: This was a pilot prospective observational clinical trial, assessing 3 months of prednisolone in adults with artificial stone–associated silicosis with PMF. Outcomes were assessed at 3 and 12 months.Results: Seven participants completed the study. Baseline positron emission tomography (PET) scans demonstrated increased fluorine-18 fluorodeoxyglucose (18F-FDG) uptake in areas of PMF in all participants. All participants had a significant reduction in maximum standardized uptake value (SUVmax) following prednisolone at 3 months (pre-treatment mean SUVmax 6.7 [standard deviation (SD): 2.6], post-treatment mean SUVmax 4.2 [SD: 1.0], p = 0.012). There was also a non-significant reduction in the % of total lung parenchyma with SUV >1 (49.7% [SD: 36.4] to 45.8% [SD: 28.4], p = 0.527) and a significant reduction in SUV >2.5 (7.0% [SD: 6.3] to 2.4% [SD: 2.2], p = 0.038). There was a non-significant reduction in computed tomography ICOERD well-defined opacity profusion scores and large opacities. There was no significant difference in lung function or St. George's Respiratory Questionnaire. There were no serious adverse events.Conclusions: There are high levels of inflammation in silicosis-PMF as evidenced by 18F-FDG PET. Short-term prednisolone reduced 18F-FDG PET activity. This suggests a possible therapeutic pathway for people with silicosis-associated PMF in a population with no current treatments. Further research is required to determine the most appropriate immunosuppressive strategy and further assess longer-term outcomes.
- Open Access
- 2 October 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (10) , e70363
The Case for Autoantibody Screening in Stone Benchtop Workers
Occupational silica exposure is a recognised cause of respiratory diseases such as silicosis, with increasing evidence linking it to systemic autoimmune diseases. We report a case of a 40‐year‐old stone benchtop fabricator diagnosed with complicated silicosis through a screening program. He was initially asymptomatic apart from Raynaud's phenomenon but had an elevated antinuclear antibody (ANA) titre. Over time, he developed progressive autoimmune disease with multisystem involvement and respiratory decline. This case highlights the potential for silica exposure to trigger severe autoimmune disease and the importance of proactive autoimmune screening in high‐risk occupational groups. ANA positivity in otherwise asymptomatic individuals may signal underlying or future autoimmune disease. Clinicians should maintain a high index of suspicion for autoimmune conditions in workers exposed to silica, as early detection offers the potential to mitigate long‐term morbidity through earlier intervention.
- 2 October 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (10) , e70363
Open AccessThe Case for Autoantibody Screening in Stone Benchtop Workers
Occupational silica exposure is a recognised cause of respiratory diseases such as silicosis, with increasing evidence linking it to systemic autoimmune diseases. We report a case of a 40‐year‐old stone benchtop fabricator diagnosed with complicated silicosis through a screening program. He was initially asymptomatic apart from Raynaud's phenomenon but had an elevated antinuclear antibody (ANA) titre. Over time, he developed progressive autoimmune disease with multisystem involvement and respiratory decline. This case highlights the potential for silica exposure to trigger severe autoimmune disease and the importance of proactive autoimmune screening in high‐risk occupational groups. ANA positivity in otherwise asymptomatic individuals may signal underlying or future autoimmune disease. Clinicians should maintain a high index of suspicion for autoimmune conditions in workers exposed to silica, as early detection offers the potential to mitigate long‐term morbidity through earlier intervention.
- Open Access
- 2 May 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (4)
Dupilumab-associated hypereosinophilia in severe asthma
Shareable abstract Dupilumab has been associated with adverse reactions including symptomatic hypereosinophilia. This study reports the incidence of dupilumab-related eosinophilia and adverse reactions in severe asthma patients at an Australian tertiary centre.https://bit.ly/3JgZ5Ya
- 2 May 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (4)
Open AccessDupilumab-associated hypereosinophilia in severe asthma
Shareable abstract Dupilumab has been associated with adverse reactions including symptomatic hypereosinophilia. This study reports the incidence of dupilumab-related eosinophilia and adverse reactions in severe asthma patients at an Australian tertiary centre.https://bit.ly/3JgZ5Ya
- Open Access
Trait profiles in difficult‐to‐treat asthma: Clinical impact and response to systematic assessment
Background: Multidisciplinary systematic assessment improves outcomes in difficult‐to‐treat asthma, but without clear response predictors. Using a treatable‐traits framework, we stratified patients by trait profile, examining clinical impact and treatment responsiveness to systematic assessment.Methods: We performed latent class analysis using 12 traits on difficult‐to‐treat asthma patients undergoing systematic assessment at our institution. We examined Asthma Control Questionnaire (ACQ‐6) and Asthma Quality of Life Questionnaire (AQLQ) scores, FEV1, exacerbation frequency, and maintenance oral corticosteroid (mOCS) dose, at baseline and following systematic assessment.Results: Among 241 patients, two airway‐centric profiles were characterized by early‐onset with allergic rhinitis (n = 46) and adult onset with eosinophilia/chronic rhinosinusitis (n = 60), respectively, with minimal comorbid or psychosocial traits; three non‐airway‐centric profiles exhibited either comorbid (obesity, vocal cord dysfunction, dysfunctional breathing) dominance (n = 51), psychosocial (anxiety, depression, smoking, unemployment) dominance (n = 72), or multi‐domain impairment (n = 12). Compared to airway‐centric profiles, non‐airway‐centric profiles had worse baseline ACQ‐6 (2.7 vs. 2.2, p < .001) and AQLQ (3.8 vs. 4.5, p < .001) scores. Following systematic assessment, the cohort showed overall improvements across all outcomes. However, airway‐centric profiles had more FEV1 improvement (5.6% vs. 2.2% predicted, p < .05) while non‐airway‐centric profiles trended to greater exacerbation reduction (1.7 vs. 1.0, p = .07); mOCS dose reduction was similar (3.1 mg vs. 3.5 mg, p = .782).Conclusion: Distinct trait profiles in difficult‐to‐treat asthma are associated with different clinical outcomes and treatment responsiveness to systematic assessment. These findings yield clinical and mechanistic insights into difficult‐to‐treat asthma, offer a conceptual framework to address disease heterogeneity, and highlight areas responsive to targeted intervention.
Open AccessTrait profiles in difficult‐to‐treat asthma: Clinical impact and response to systematic assessment
Background: Multidisciplinary systematic assessment improves outcomes in difficult‐to‐treat asthma, but without clear response predictors. Using a treatable‐traits framework, we stratified patients by trait profile, examining clinical impact and treatment responsiveness to systematic assessment.Methods: We performed latent class analysis using 12 traits on difficult‐to‐treat asthma patients undergoing systematic assessment at our institution. We examined Asthma Control Questionnaire (ACQ‐6) and Asthma Quality of Life Questionnaire (AQLQ) scores, FEV1, exacerbation frequency, and maintenance oral corticosteroid (mOCS) dose, at baseline and following systematic assessment.Results: Among 241 patients, two airway‐centric profiles were characterized by early‐onset with allergic rhinitis (n = 46) and adult onset with eosinophilia/chronic rhinosinusitis (n = 60), respectively, with minimal comorbid or psychosocial traits; three non‐airway‐centric profiles exhibited either comorbid (obesity, vocal cord dysfunction, dysfunctional breathing) dominance (n = 51), psychosocial (anxiety, depression, smoking, unemployment) dominance (n = 72), or multi‐domain impairment (n = 12). Compared to airway‐centric profiles, non‐airway‐centric profiles had worse baseline ACQ‐6 (2.7 vs. 2.2, p < .001) and AQLQ (3.8 vs. 4.5, p < .001) scores. Following systematic assessment, the cohort showed overall improvements across all outcomes. However, airway‐centric profiles had more FEV1 improvement (5.6% vs. 2.2% predicted, p < .05) while non‐airway‐centric profiles trended to greater exacerbation reduction (1.7 vs. 1.0, p = .07); mOCS dose reduction was similar (3.1 mg vs. 3.5 mg, p = .782).Conclusion: Distinct trait profiles in difficult‐to‐treat asthma are associated with different clinical outcomes and treatment responsiveness to systematic assessment. These findings yield clinical and mechanistic insights into difficult‐to‐treat asthma, offer a conceptual framework to address disease heterogeneity, and highlight areas responsive to targeted intervention.
- 22 December 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (12) , 2133-2139
Repeated adrenaline requirements for anaphylaxis
We examined the pattern of adrenaline administration in patients presenting with anaphylaxis. Forty-four percent required repeated adrenaline administration, among whom there had been greater cardiorespiratory compromise. Repeated administration was more frequent in males and older patients, and those triggered by insect sting or unknown cause; no other patient factors were identified. This study supports the provision of two adrenaline auto-injectors to all anaphylaxis patients.
- 22 December 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (12) , 2133-2139
Repeated adrenaline requirements for anaphylaxis
We examined the pattern of adrenaline administration in patients presenting with anaphylaxis. Forty-four percent required repeated adrenaline administration, among whom there had been greater cardiorespiratory compromise. Repeated administration was more frequent in males and older patients, and those triggered by insect sting or unknown cause; no other patient factors were identified. This study supports the provision of two adrenaline auto-injectors to all anaphylaxis patients.
- 1 February 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 177, 106286
Updated prevalence, predictors and treatment outcomes for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation
- 1 February 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 177, 106286
Updated prevalence, predictors and treatment outcomes for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation
- Open Access
- 28 May 2020
- Published by BMJ in BMJ Neurology Open
- Vol. 2 (1) , e000066
Moyamoya vasculopathy in a young Caucasian woman with significant methamphetamine use
Background Moyamoya is a rare cerebrovascular disorder seen predominantly in Asian populations. Methamphetamine use is a recognised cause of stroke in young people, but its pathophysiology is not fully understood. The incidence of moyamoya vasculopathy in methamphetamine-associated stroke is unknown due to a lack of sufficient data. We present a rare case of moyamoya syndrome in a young Caucasian woman with methamphetamine-associated stroke. Case A 31-year-old Caucasian woman presented with progressive right arm weakness, speech disturbance and seizures on a background of escalating methamphetamine use in the 9 months prior to admission. She did not have a personal or family history of stroke. MRI revealed both embolic and watershed infarcts in bilateral frontal regions and CT angiography showed development of new lenticulostriate collateral vessels. Digital subtraction angiography confirmed steno-occlusive disease of the bilateral anterior circulations and a ‘puff of smoke’ appearance. Conclusion In young patients who present with stroke with unclear aetiology, it is important to obtain a thorough substance use history. Moyamoya vasculopathy should be considered when evaluating the pathophysiology of stroke in young people.
- 28 May 2020
- Published by BMJ in BMJ Neurology Open
- Vol. 2 (1) , e000066
Open AccessMoyamoya vasculopathy in a young Caucasian woman with significant methamphetamine use
Background Moyamoya is a rare cerebrovascular disorder seen predominantly in Asian populations. Methamphetamine use is a recognised cause of stroke in young people, but its pathophysiology is not fully understood. The incidence of moyamoya vasculopathy in methamphetamine-associated stroke is unknown due to a lack of sufficient data. We present a rare case of moyamoya syndrome in a young Caucasian woman with methamphetamine-associated stroke. Case A 31-year-old Caucasian woman presented with progressive right arm weakness, speech disturbance and seizures on a background of escalating methamphetamine use in the 9 months prior to admission. She did not have a personal or family history of stroke. MRI revealed both embolic and watershed infarcts in bilateral frontal regions and CT angiography showed development of new lenticulostriate collateral vessels. Digital subtraction angiography confirmed steno-occlusive disease of the bilateral anterior circulations and a ‘puff of smoke’ appearance. Conclusion In young patients who present with stroke with unclear aetiology, it is important to obtain a thorough substance use history. Moyamoya vasculopathy should be considered when evaluating the pathophysiology of stroke in young people.